AnaptysBio Company Insiders
ANAB Stock | USD 20.61 0.19 0.93% |
AnaptysBio employs about 136 people. The company is managed by 13 executives with a total tenure of roughly 7 years, averaging almost 0.0 years of service per executive, having 10.46 employees per reported executive. Analysis of AnaptysBio's management performance can provide insight into the company performance.
Eric Loumeau Executive General Counsel |
AnaptysBio | Build AI portfolio with AnaptysBio Stock |
AnaptysBio Management Team Effectiveness
The company has return on total asset (ROA) of (0.1535) % which means that it has lost $0.1535 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8271) %, meaning that it created substantial loss on money invested by shareholders. AnaptysBio's management efficiency ratios could be used to measure how well AnaptysBio manages its routine affairs as well as how well it operates its assets and liabilities.AnaptysBio Workforce Comparison
AnaptysBio is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 1,522. AnaptysBio holds roughly 136 in number of employees claiming about 9% of equities under Health Care industry.
The company has Profit Margin (PM) of (1.59) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.22) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.22. AnaptysBio Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AnaptysBio insiders, such as employees or executives, is commonly permitted as long as it does not rely on AnaptysBio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, AnaptysBio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Eric Loumeau over a month ago Disposition of 6000 shares by Eric Loumeau of AnaptysBio subject to Rule 16b-3 | ||
Eric Loumeau over a month ago Disposition of 5000 shares by Eric Loumeau of AnaptysBio at 14.02 subject to Rule 16b-3 | ||
Lizzul Paul F. over a month ago Acquisition by Lizzul Paul F. of 1500 shares of AnaptysBio at 18.5 subject to Rule 16b-3 | ||
Daniel Faga over two months ago Acquisition by Daniel Faga of 107350 shares of AnaptysBio subject to Rule 16b-3 | ||
Daniel Faga over three months ago Disposition of 6387 shares by Daniel Faga of AnaptysBio at 15.3 subject to Rule 16b-3 | ||
Schmid John P. over three months ago Acquisition by Schmid John P. of 16510 shares of AnaptysBio at 14.83 subject to Rule 16b-3 | ||
Eric Loumeau over three months ago Acquisition by Eric Loumeau of 7288 shares of AnaptysBio subject to Rule 16b-3 | ||
Daniel Faga over three months ago Disposition of 17850 shares by Daniel Faga of AnaptysBio subject to Rule 16b-3 |
AnaptysBio Notable Stakeholders
An AnaptysBio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AnaptysBio often face trade-offs trying to please all of them. AnaptysBio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AnaptysBio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Martin Dahl | Senior Research | Profile | |
Monique Silva | Senior Affairs | Profile | |
James MD | Advisor | Profile | |
Beth Mueller | Senior Resources | Profile | |
Priya Raina | Senior Operations | Profile | |
FAAD MBA | Chief Officer | Profile | |
Daniel Faga | Interim Director | Profile | |
MSc MBA | Advisory | Profile | |
Dennis Mulroy | Chief Officer | Profile | |
Douglas MBA | Senior CMC | Profile | |
Eric Loumeau | General Counsel | Profile | |
Benjamin Stone | Chief Officer | Profile | |
MSc MD | Senior Development | Profile |
About AnaptysBio Management Performance
The success or failure of an entity such as AnaptysBio often depends on how effective the management is. AnaptysBio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AnaptysBio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AnaptysBio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. Anaptysbio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 102 people.
Please note, the presentation of AnaptysBio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AnaptysBio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of AnaptysBio's management manipulating its earnings.
AnaptysBio Workforce Analysis
Traditionally, organizations such as AnaptysBio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AnaptysBio within its industry.AnaptysBio Manpower Efficiency
Return on AnaptysBio Manpower
Revenue Per Employee | 671.2K | |
Revenue Per Executive | 7M | |
Net Loss Per Employee | 1.1M | |
Net Loss Per Executive | 11.2M | |
Working Capital Per Employee | 2.8M | |
Working Capital Per Executive | 29.7M |
Complementary Tools for AnaptysBio Stock analysis
When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |